bs-9535R-Cy3 [Conjugated Primary Antibody]
alpha-TAT Polyclonal Antibody, Cy3 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: alpha-TAT

Immunogen Range: 1-100/421


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 79969

Swiss Prot: Q5SQI0

Source: KLH conjugated synthetic peptide derived from human alpha-TAT

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

Making up nearly 6% of the human genome, chromosome 6 contains around 1,200 genes within 170 million base pairs of sequence. Deletion of a portion of the q arm of chromosome 6 is associated with early onset intestinal cancer suggesting the presence of a cancer susceptibility locus. Porphyria cutanea tarda is associated with chromosome 6 through the HFE gene which, when mutated, predisposes an individual to developing this porphyria. Notably, the PARK2 gene, which is associated with Parkinson's disease, and the genes encoding the major histocompatiblity complex proteins, which are key molecular components of the immune system and determine predisposition to rheumatic diseases, are also located on chromosome 6. Stickler syndrome, 21-hydroxylase deficiency and maple syrup urine disease are also associated with genes on chromosome 6. A bipolar disorder susceptibility locus has been identified on the q arm of chromosome 6. The C6orf134 gene product has been provisionally designated C6orf134 pending further characterization.

Conjugation: Cy3

Excitation/ Emission: 512,550nm/570,615nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
IF(IHC-P)(1:50-200)

Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Wang HH et al. Rab23/Kif17 regulate oocyte meiotic progression by modulating tubulin acetylation and actin dynamics. Development. 2019 Feb 4;146(3). Read more>>
  • Jos Martnez-Hernndez. et al. Crosstalk between acetylation and the tyrosination/detyrosination cycle of -tubulin in Alzheimer's disease.. FRONT CELL DEV BIOL. 2022 Aug;10:926914-926914Read more>>
  • Atul Kumar. et al. MFN2 coordinates mitochondria motility with -tubulin acetylation and this regulation is disrupted in CMT2A. ISCIENCE. 2024 Jun;27Read more>>
VALIDATION IMAGES